Fulgent Genetics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Fulgent Genetics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $4.28M | Mar 20, 2018 |
| FY2017 | Sep 30, 2017 | $4.50M | Mar 20, 2018 |
| FY2017 | Jun 30, 2017 | $4.64M | Mar 20, 2018 |
| FY2017 | Mar 31, 2017 | $5.31M | Mar 20, 2018 |
| FY2017 | Dec 31, 2016 | $5.85M | Mar 20, 2018 |
| FY2017 | Sep 30, 2016 | $5.01M | Mar 20, 2018 |
| FY2017 | Jun 30, 2016 | $3.97M | Mar 20, 2018 |
| FY2017 | Mar 31, 2016 | $3.44M | Mar 20, 2018 |
| FY2016 | Dec 31, 2015 | $2.90M | Mar 17, 2017 |
| FY2016 | Sep 30, 2015 | $2.91M | Mar 17, 2017 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $322.67M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $283.47M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $289.21M | Feb 27, 2026 |
| FY2022 | Dec 31, 2022 | $67.70M | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | $105.66M | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $125.34M | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | $320.27M | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $251.67M | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | $227.87M | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | $153.62M | Feb 28, 2023 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $130.88M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $107.22M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $104.46M | Feb 27, 2026 |
| FY2022 | Dec 31, 2022 | $12.99M | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | $46.10M | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $65.28M | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | $242.54M | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $189.54M | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | $184.40M | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | $117.76M | Feb 28, 2023 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($60.51M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($42.71M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($167.83M) | Feb 27, 2026 |
| FY2022 | Dec 31, 2022 | ($23.83M) | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | $1.72M | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $11.54M | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | $153.98M | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $104.34M | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | $122.52M | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | $79.81M | Feb 28, 2023 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($91.10M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($73.92M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($195.53M) | Feb 27, 2026 |
| FY2022 | Dec 31, 2022 | ($36.55M) | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | $352.0K | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $12.79M | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | $201.93M | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $150.86M | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | $159.27M | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | $98.90M | Feb 28, 2023 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $53.91M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $48.82M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $41.44M | Feb 27, 2026 |
| FY2022 | Dec 31, 2022 | $8.51M | Feb 28, 2023 |
| FY2022 | Sep 30, 2022 | $7.51M | Feb 28, 2023 |
| FY2022 | Jun 30, 2022 | $6.91M | Feb 28, 2023 |
| FY2022 | Mar 31, 2022 | $5.99M | Feb 28, 2023 |
| FY2022 | Dec 31, 2021 | $7.46M | Feb 28, 2023 |
| FY2022 | Sep 30, 2021 | $6.02M | Feb 28, 2023 |
| FY2022 | Jun 30, 2021 | $5.31M | Feb 28, 2023 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($101.64M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $21.06M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $27.00M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $253.52M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $538.58M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $140.63M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $5.52M | Feb 28, 2022 |
| FY2019 | Dec 31, 2018 | ($675.0K) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $1.33M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $4.41M | Mar 20, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $22.57M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $40.32M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $22.21M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $18.78M | Feb 28, 2025 |
| FY2023 | Dec 31, 2021 | $23.81M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | $35.13M | Feb 28, 2023 |
| FY2021 | Dec 31, 2019 | $1.18M | Feb 28, 2022 |
| FY2019 | Dec 31, 2018 | $2.32M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $2.90M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $3.79M | Mar 20, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.21B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.22B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.24B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.39B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.28B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $700.46M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $88.76M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $53.90M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $57.18M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $58.04M | Mar 20, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $106.81M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $90.81M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $102.04M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $116.18M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $112.84M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $131.07M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $5.98M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $2.75M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $3.01M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $3.56M | Mar 20, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.11B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $1.13B | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $1.14B | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $1.27B | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $1.16B | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $569.39M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $82.78M | Mar 8, 2021 |
| FY2020 | Dec 31, 2018 | $51.15M | Mar 8, 2021 |
| FY2019 | Dec 31, 2017 | $54.18M | Mar 13, 2020 |
| FY2018 | Dec 31, 2016 | $54.48M | Mar 22, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $25.08M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $22.06M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $22.06M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $143.03M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $50.90M | Feb 28, 2023 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $529.95M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $590.47M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $633.18M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | $801.00M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $657.60M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $150.88M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | ($63.43M) | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | ($63.02M) | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | ($57.66M) | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | ($55.15M) | Mar 20, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.19M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $55.14M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $97.47M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $79.51M | Feb 28, 2025 |
| FY2022 | Dec 31, 2021 | $164.89M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | $87.43M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | $11.97M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | $6.74M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | $6.49M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | $7.90M | Mar 20, 2018 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | 0 | Mar 22, 2019 |
| FY2018 | Sep 30, 2018 | 0 | Mar 22, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Mar 22, 2019 |
| FY2018 | Mar 31, 2018 | 0 | Mar 22, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Mar 22, 2019 |
| FY2018 | Sep 30, 2017 | 0 | Mar 22, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Mar 22, 2019 |
| FY2018 | Mar 31, 2017 | 0 | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 20, 2018 |
| FY2017 | Sep 30, 2016 | 0 | Mar 20, 2018 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2018 | Dec 31, 2018 | 0 | Mar 22, 2019 |
| FY2018 | Sep 30, 2018 | 0 | Mar 22, 2019 |
| FY2018 | Jun 30, 2018 | 0 | Mar 22, 2019 |
| FY2018 | Mar 31, 2018 | 0 | Mar 22, 2019 |
| FY2018 | Dec 31, 2017 | 0 | Mar 22, 2019 |
| FY2018 | Sep 30, 2017 | 0 | Mar 22, 2019 |
| FY2018 | Jun 30, 2017 | 0 | Mar 22, 2019 |
| FY2018 | Mar 31, 2017 | 0 | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | 0 | Mar 20, 2018 |
| FY2017 | Sep 30, 2016 | 0 | Mar 20, 2018 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 31.08M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 30.84M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 29.65M | Feb 28, 2025 |
| FY2023 | Dec 31, 2022 | 29.44M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 30.16M | Feb 28, 2023 |
| FY2021 | Dec 31, 2020 | 28.18M | Feb 28, 2022 |
| FY2020 | Dec 31, 2019 | 21.48M | Mar 8, 2021 |
| FY2019 | Dec 31, 2018 | 18.17M | Mar 13, 2020 |
| FY2018 | Dec 31, 2017 | 17.85M | Mar 22, 2019 |
| FY2017 | Dec 31, 2016 | 17.68M | Mar 20, 2018 |